Merck ROE 2010-2023 | MRK
Current and historical return on equity (ROE) values for Merck (MRK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Merck ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-12-31 |
$0.37B |
$37.64B |
0.89% |
| 2023-09-30 |
$4.61B |
$41.30B |
10.65% |
| 2023-06-30 |
$3.11B |
$38.74B |
7.06% |
| 2023-03-31 |
$13.03B |
$46.91B |
28.83% |
| 2022-12-31 |
$14.52B |
$46.06B |
33.21% |
| 2022-09-30 |
$15.26B |
$44.52B |
36.54% |
| 2022-06-30 |
$16.58B |
$43.32B |
41.87% |
| 2022-03-31 |
$14.18B |
$40.95B |
38.21% |
| 2021-12-31 |
$13.05B |
$38.26B |
38.79% |
| 2021-09-30 |
$7.20B |
$35.86B |
23.65% |
| 2021-06-30 |
$5.57B |
$33.39B |
19.36% |
| 2021-03-31 |
$7.03B |
$27.04B |
25.68% |
| 2020-12-31 |
$7.07B |
$25.40B |
26.00% |
| 2020-09-30 |
$11.52B |
$29.27B |
42.15% |
| 2020-06-30 |
$10.48B |
$27.74B |
39.18% |
| 2020-03-31 |
$10.15B |
$26.30B |
37.95% |
| 2019-12-31 |
$9.84B |
$26.00B |
36.34% |
| 2019-09-30 |
$9.31B |
$26.93B |
34.11% |
| 2019-06-30 |
$9.36B |
$27.74B |
32.58% |
| 2019-03-31 |
$8.40B |
$27.67B |
28.00% |
| 2018-12-31 |
$6.22B |
$26.88B |
19.71% |
| 2018-09-30 |
$3.35B |
$32.66B |
10.00% |
| 2018-06-30 |
$1.34B |
$32.77B |
3.84% |
| 2018-03-31 |
$1.58B |
$33.90B |
4.31% |
| 2017-12-31 |
$2.39B |
$34.57B |
6.26% |
| 2017-09-30 |
$2.85B |
$38.50B |
7.18% |
| 2017-06-30 |
$5.09B |
$39.71B |
12.40% |
| 2017-03-31 |
$4.35B |
$40.09B |
10.36% |
| 2016-12-31 |
$3.92B |
$40.31B |
9.14% |
| 2016-09-30 |
$5.49B |
$43.96B |
12.47% |
| 2016-06-30 |
$5.13B |
$43.45B |
11.55% |
| 2016-03-31 |
$4.61B |
$43.90B |
10.20% |
| 2015-12-31 |
$4.44B |
$44.77B |
9.60% |
| 2015-09-30 |
$10.78B |
$45.68B |
22.82% |
| 2015-06-30 |
$9.85B |
$46.64B |
20.88% |
| 2015-03-31 |
$11.17B |
$47.92B |
23.44% |
| 2014-12-31 |
$11.92B |
$48.79B |
24.42% |
| 2014-09-30 |
$5.39B |
$45.36B |
10.84% |
| 2014-06-30 |
$5.61B |
$48.52B |
11.04% |
| 2014-03-31 |
$4.52B |
$52.56B |
8.81% |
| 2013-12-31 |
$4.40B |
$52.33B |
8.47% |
| 2013-09-30 |
$4.53B |
$50.01B |
8.58% |
| 2013-06-30 |
$5.14B |
$50.11B |
9.36% |
| 2013-03-31 |
$6.02B |
$55.61B |
10.61% |
| 2012-12-31 |
$6.17B |
$55.46B |
10.78% |
| 2012-09-30 |
$6.76B |
$58.21B |
11.75% |
| 2012-06-30 |
$6.72B |
$57.67B |
11.71% |
| 2012-03-31 |
$6.95B |
$57.31B |
12.10% |
| 2011-12-31 |
$6.26B |
$56.94B |
10.91% |
| 2011-09-30 |
$4.22B |
$57.60B |
7.36% |
| 2011-06-30 |
$2.87B |
$57.92B |
5.00% |
| 2011-03-31 |
$1.60B |
$56.84B |
2.80% |
| 2010-12-31 |
$0.86B |
$56.81B |
1.48% |
| 2010-09-30 |
$7.84B |
$58.05B |
13.20% |
| 2010-06-30 |
$10.92B |
$57.67B |
21.33% |
| 2010-03-31 |
$11.73B |
$60.34B |
27.60% |
| 2009-12-31 |
$12.85B |
$61.49B |
39.07% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$317.211B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
